RudolphMNavariMD

Professor, Medicine, Indiana University School of Medicine

Dr. Navari is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
832 Princeton Ave
Birmingham, AL 35211
Phone+1 205-397-8934

Fax+1 205-206-8300

Dr. Rudolph Navari is an oncologist in Birmingham, AL and is affiliated with multiple hospitals in the area, including St. Vincent Kokomo, Saint Joseph Health System, University of Alabama Hospital, and University of Alabama Hospital. He received his medical degree from Virginia Commonwealth University School of Medicine and has been in practice 40 years. He specializes in hematologic oncology.

University of WashingtonFellowship, Hematology and Medical Oncology, 1981 - 1983
University of Alabama Medical CenterResidency, Internal Medicine, 1977 - 1980
Virginia Commonwealth University School of MedicineClass of 1977

PubMed

204 citations
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari, Matti S. Aapro
The New England Journal of Medicine. 2016-04-06
25 citations
Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
Rudolph M. Navari
Paediatric Drugs. 2017-04-21
35 citations
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
Rudolph M. Navari
Biochimica Et Biophysica Acta. 2015-10-01

Journal Articles

The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting—Reply
Charles L Loprinzi, Rudolph M Navari, JAMA Oncology
Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting
Rudolph M Navari, Costantine Albany, Charles L Loprinzi, JAMA Oncology

Lectures

Physician concordance with update to ASCO guidelines for antiemetic use with carboplatin AUC â‰¥ 4.
2019 ASCO Annual Meeting - 6/1/2019

Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingMay 2020
Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingMay 2020

Helsinn Publishes Results from a Secondary Analysis of a Phase 3 Trial in Patients with CINV Helsinn Publishes Results from a Secondary Analysis of a Phase 3 Trial in Patients with CINVJanuary 4th, 2023
FDA Updates Highlighting the Latest Cancer TreatmentsNovember 20th, 2019
Study Finds Guideline Adoption Slow for Antiemetic Prophylaxis in Patients Receiving CarboplatinNovember 2nd, 2018
Join now to see all